- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00713635
Prenatal Effects of Congenital Heart Disease (CHD) on Neurodevelopmental Outcome
The Prenatal Effects of Congenital Heart Disease on Neurodevelopmental Outcome
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Congenital heart disease (CHD) is the most common class of birth defect and is a major cause of infant and child death and morbidity, including neurodevelopmental delay. Children with severe forms of CHD are at high risk for a spectrum of neurocognitive difficulties that include learning disability, attention deficit and hyperactivity disorder, behavioral problems and mental retardation. The etiology of neurodevelopmental delay in children with CHD is not fully understood but is thought to be secondary to a combination of pre- and post-natal insults to the brain. It has been observed that fetuses with severe forms of CHD have abnormal blood flow to the brain as measured by Doppler ultrasound. This "centralization" or redirection of blood flow toward vital organs such as the brain has been shown to lead to abnormal brain development in other fetal diseases, such as intrauterine growth restriction. Evidence of the importance of prenatal brain development in the setting of CHD is amounting. Neonates with complex CHD demonstrate abnormalities of brain structure and blood flow prior to cardiothoracic surgery. However, to date, associations between abnormal fetal brain blood flow and neonatal neurologic outcomes and brain function have not been established in the CHD population. Finally, newborns with CHD have been shown to have abnormalities in heart rate over a 24 hour period. This finding suggests that the autonomic nervous system, which controls heart rate and blood pressure, may not function properly in infants with CHD.
The study proposes that these changes in blood flows in the fetus with heart disease could be responsible in part for poor brain growth, abnormal brain structure and function and developmental delay in childhood. Investigators will use routine obstetrical ultrasound and fetal echocardiograms to evaluate blood flow to vital organs and brain growth in fetuses with CHD. Investigators will use non-invasive fetal monitors to measure fetal heart rate and movement. Investigators will look at brain structure using Magnetic Resonance Imaging (MRI) in the fetus and newborn. Afterbirth, investigators will use non-invasive monitors to measure neonatal heart rate and blood pressure changes in response to a tilt, similar to what is experienced when placing an infant in a car seat. Investigators will use a non-invasive monitor consisting of a sticker applied to the skin to measure the level of oxygen in the brain. Investigators will also measure brain function in the newborn with an electroencephalogram(EEG) that records the electrical signaling between different parts of the brain using a special plastic hat like a swim cap. Regular physical exams with a pediatrician to measure growth and development will take place. A special test designed to detect learning disabilities will also be done when the child is 14 months old. This test will consist of talking with the child, reading stories, and showing the child pictures and colors. There will be no extra blood tests needed and none of the tests pose any risk to the mother, fetus, infant, or child.
The possible benefits to the child and the family will be early identification of any brain abnormality in the newborn period as well as learning disabilities in the toddler which will then allow the child to receive therapies designed to treat these problems. Studies show that early identification and treatment of learning disabilities are important to enhance the potential of the child.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- Columbia University College of Physicians & Surgeons, Morgan Stanley Children's Hospital of New York
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- All women who present to Columbia University Medical Center between 18-24 wks gestational age with the following fetal diagnoses will be invited to participate:
- Hypoplastic Left Heart Syndrome (HLHS)
- Transposition of the Great Arteries (TGA)
- Tetralogy of Fallot (TOF)
- Lung anomalies consisting of either congenital cystic adenomatoid malformations or bronchogenic cysts
Exclusion Criteria:
- Documented fetal chromosomal anomaly
- Structural brain malformations
- Evidence of placental insufficiency or Intrauterine growth retardation
- Documented hydrops fetalis or sustained cardiac arrhythmias
- Anticipated delivery at an outside hospital
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
1
Fetuses and neonates with congenital heart disease consisting of hypoplastic left heart syndrome (HLHS)
|
|
2
Fetuses and neonates with congenital heart disease consisting of transposition of the great arteries (TGA)
|
|
3
Fetuses and neonates with congenital heart disease consisting of tetralogy of fallot
|
|
4
Fetuses and neonates with lung masses but without congenital heart disease will serve as a control group
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Neurodevelopmental scores as measured by the Bayley Scales of Infant Development
Zeitfenster: 18 months of age
|
18 months of age
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Neurologic Function as defined by neonatal electroencephalographic power and coherence as measured by a neonatal high-density EEG
Zeitfenster: Neonatal EEG within 72 hours of birth
|
Neonatal EEG within 72 hours of birth
|
|
Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test)
Zeitfenster: Fetal assessment between 18-24 wk GA
|
Fetal assessment between 18-24 wk GA
|
|
Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test)
Zeitfenster: Fetal assessment between 28-32 wk GA
|
Fetal assessment between 28-32 wk GA
|
|
Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test)
Zeitfenster: Fetal assessment between 34-38 wk GA
|
Fetal assessment between 34-38 wk GA
|
|
Neurologic Function as defined by neonatal electroencephalographic power and coherence as measured by a neonatal high-density EEG
Zeitfenster: Neonatal EEG at 1 month of age
|
Neonatal EEG at 1 month of age
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Ismee A Williams, MD, MS, Columbia University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- AAAD1879
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Angeborenen Herzfehler
-
Region SkaneAnmeldung auf EinladungHerzinsuffizienz New York Heart Association (NYHA) Klasse II | Herzinsuffizienz New York Heart Association (NYHA) Klasse IIISchweden
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus... und andere MitarbeiterBeendetHerzinsuffizienz, systolisch | Herzinsuffizienz mit reduzierter Ejektionsfraktion | Herzinsuffizienz New York Heart Association Klasse IV | Herzinsuffizienz New York Heart Association Klasse IIIPolen
-
China National Center for Cardiovascular DiseasesChinese Academy of Medical Sciences, Fuwai HospitalAktiv, nicht rekrutierendLungenentzündung | Sepsis | Infektion | Driveline Heart-assisted Device Related InfectionChina
-
University of WashingtonAmerican Heart AssociationAbgeschlossenHerzinsuffizienz, kongestive | Mitochondriale Veränderung | Herzinsuffizienz New York Heart Association Klasse IVVereinigte Staaten
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Portuguese Association of Interventional CardiologyMedtronicRekrutierungSchwere symptomatische Aortenstenose (definiert als New York Heart Association (NYHA) Klasse ≥ II)Portugal
-
University Hospital, GasthuisbergUnbekanntTransient Left Ventricular Ballooning SyndromeBelgien
-
Medical University of South CarolinaAmerican Heart AssociationAbgeschlossenSingle Ventricle Heart Disease nach Fontan-OperationVereinigte Staaten
-
NYU Langone HealthRekrutierungTako-Tsubo-Kardiomyopathie | Takotsubo-Kardiomyopathie | Broken-Heart-SyndromVereinigte Staaten
-
Mezzion Pharma Co. LtdNational Heart, Lung, and Blood Institute (NHLBI); Pediatric Heart NetworkAbgeschlossenSingle Ventricle Heart Disease nach Fontan-OperationVereinigte Staaten, Kanada